Tag Archives: BioTheranostics

January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.

August 2016—A study published in Oncotarget (Brachtel EF, et al. Epub ahead of print March 28, 2016) demonstrates the high accuracy and success rate of Biotheranostics’ CancerType ID molecular cancer classifier in the diagnosis of cancer for specimens with limited tissue. Results from the study support additional clinical utility for CancerType ID in small biopsy and cytology cases.

February 2016—BioTheranostics announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, BioTheranostics will be spun out from BioMérieux, which will remain a minority shareholder, and operate as an independent company.

December 2015—BioTheranostics announced a collaboration agreement with Celsee Diagnostics (formerly DeNovo Sciences) to investigate the technical feasibility of using BioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics.

July 2015—BioTheranostics announced that clinical study data disclosed at the American Society of Clinical Oncology annual meeting in June demonstrate that its CancerType ID molecular cancer classifier and CancerTreatment NGS+ biomarker tests provide actionable genomic information to support an accurate diagnosis and treatment of metastatic cancers.

January 2015—Results from three studies presented at the 37th Annual San Antonio Breast Cancer Symposium on BioTheranostics’ Breast Cancer Index molecular test provided additional evidence of its predictive and prognostic abilities.

October 2014—The bioT3 Metastatic Cancer Solution from BioTheranostics now includes a single assay that covers genetic mutations and protein expression.

March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.

December 2013—BioTheranostics announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

BioTheranostics, a provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID molecular cancer classifier. CancerType ID predicts tumor type in patients with metastatic cancers.

BioTheranostics’ Prostate Cancer Index is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk of recurrence and metastasis in patients with prostate cancer, according to a study published online in the Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1215870110. Epub March 26, 2013).